Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients

Jung Ho Im, Hong In Yoon, Sunghoon Kim, Eun Ji Nam, Sang Wun Kim, Ga Won Yim, Ki Chang Keum, YoungTae Kim, Gwi Eon Kim, Yongbae Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: To investigate the role of radiotherapy (RT) in and to suggest radiotherapeutic strategies for patients presenting with disseminated cervical cancer. Methods: We retrospectively analyzed 50 patients diagnosed as the disseminated cervical cancer with distant lymph nodal or visceral organ metastasis between September 1980 and August 2012. Patients were divided into two subgroups according to visceral organ metastasis: 35 patients diagnosed with distant lymph node metastasis only (group A) and 15 patients with visceral organ metastasis (group B). All patients received external beam RT to the pelvis (median dose 45 Gy) and high-dose rate intracavitary RT (median dose 30 Gy). Thirty-nine patients (78%) received chemotherapy. Results: Median follow-up time was 74 months. The 5-year pelvic control rate (PCR) was 85.8%, and the progression-free survival (PFS), and overall survival (OS) rates were 28.7%, and 36.2%, respectively. The major treatment failure was systemic progression (32 patients, 64%). The 5-year PCRs in groups A and B were 87.4% and 74.7%, respectively (p>0.05). Meanwhile, PFS and OS rates for group A were significantly better than those for group B (35.3% vs. 13.3%, p=0.010; and 46.3% vs. 13.3%, p=0.009, respectively). Conclusion: Our data revealed considerable prognostic heterogeneity in disseminated cervical cancer. Even though a high PCR was achieved in patients treated with definitive RT, survival outcomes were dependent on progression of visceral organ metastasis. Therefore, personalized RT and chemotherapy treatment strategies according to the presence of visceral organ metastasis in disseminated cervical cancer patients may help improve clinical outcomes.

Original languageEnglish
Article number77
JournalRadiation Oncology
Volume10
Issue number1
DOIs
Publication statusPublished - 2015 Apr 4

Fingerprint

Uterine Cervical Neoplasms
Neoplasm Metastasis
Radiotherapy
Disease-Free Survival
Survival Rate
Drug Therapy
Lymph
Treatment Failure
Pelvis
Lymph Nodes
Polymerase Chain Reaction
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Im, Jung Ho ; Yoon, Hong In ; Kim, Sunghoon ; Nam, Eun Ji ; Kim, Sang Wun ; Yim, Ga Won ; Keum, Ki Chang ; Kim, YoungTae ; Kim, Gwi Eon ; Kim, Yongbae. / Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients. In: Radiation Oncology. 2015 ; Vol. 10, No. 1.
@article{f5fc9742705b4328b77634ff87b59f5b,
title = "Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients",
abstract = "Background: To investigate the role of radiotherapy (RT) in and to suggest radiotherapeutic strategies for patients presenting with disseminated cervical cancer. Methods: We retrospectively analyzed 50 patients diagnosed as the disseminated cervical cancer with distant lymph nodal or visceral organ metastasis between September 1980 and August 2012. Patients were divided into two subgroups according to visceral organ metastasis: 35 patients diagnosed with distant lymph node metastasis only (group A) and 15 patients with visceral organ metastasis (group B). All patients received external beam RT to the pelvis (median dose 45 Gy) and high-dose rate intracavitary RT (median dose 30 Gy). Thirty-nine patients (78{\%}) received chemotherapy. Results: Median follow-up time was 74 months. The 5-year pelvic control rate (PCR) was 85.8{\%}, and the progression-free survival (PFS), and overall survival (OS) rates were 28.7{\%}, and 36.2{\%}, respectively. The major treatment failure was systemic progression (32 patients, 64{\%}). The 5-year PCRs in groups A and B were 87.4{\%} and 74.7{\%}, respectively (p>0.05). Meanwhile, PFS and OS rates for group A were significantly better than those for group B (35.3{\%} vs. 13.3{\%}, p=0.010; and 46.3{\%} vs. 13.3{\%}, p=0.009, respectively). Conclusion: Our data revealed considerable prognostic heterogeneity in disseminated cervical cancer. Even though a high PCR was achieved in patients treated with definitive RT, survival outcomes were dependent on progression of visceral organ metastasis. Therefore, personalized RT and chemotherapy treatment strategies according to the presence of visceral organ metastasis in disseminated cervical cancer patients may help improve clinical outcomes.",
author = "Im, {Jung Ho} and Yoon, {Hong In} and Sunghoon Kim and Nam, {Eun Ji} and Kim, {Sang Wun} and Yim, {Ga Won} and Keum, {Ki Chang} and YoungTae Kim and Kim, {Gwi Eon} and Yongbae Kim",
year = "2015",
month = "4",
day = "4",
doi = "10.1186/s13014-015-0373-0",
language = "English",
volume = "10",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients. / Im, Jung Ho; Yoon, Hong In; Kim, Sunghoon; Nam, Eun Ji; Kim, Sang Wun; Yim, Ga Won; Keum, Ki Chang; Kim, YoungTae; Kim, Gwi Eon; Kim, Yongbae.

In: Radiation Oncology, Vol. 10, No. 1, 77, 04.04.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tailored radiotherapeutic strategies for disseminated uterine cervical cancer patients

AU - Im, Jung Ho

AU - Yoon, Hong In

AU - Kim, Sunghoon

AU - Nam, Eun Ji

AU - Kim, Sang Wun

AU - Yim, Ga Won

AU - Keum, Ki Chang

AU - Kim, YoungTae

AU - Kim, Gwi Eon

AU - Kim, Yongbae

PY - 2015/4/4

Y1 - 2015/4/4

N2 - Background: To investigate the role of radiotherapy (RT) in and to suggest radiotherapeutic strategies for patients presenting with disseminated cervical cancer. Methods: We retrospectively analyzed 50 patients diagnosed as the disseminated cervical cancer with distant lymph nodal or visceral organ metastasis between September 1980 and August 2012. Patients were divided into two subgroups according to visceral organ metastasis: 35 patients diagnosed with distant lymph node metastasis only (group A) and 15 patients with visceral organ metastasis (group B). All patients received external beam RT to the pelvis (median dose 45 Gy) and high-dose rate intracavitary RT (median dose 30 Gy). Thirty-nine patients (78%) received chemotherapy. Results: Median follow-up time was 74 months. The 5-year pelvic control rate (PCR) was 85.8%, and the progression-free survival (PFS), and overall survival (OS) rates were 28.7%, and 36.2%, respectively. The major treatment failure was systemic progression (32 patients, 64%). The 5-year PCRs in groups A and B were 87.4% and 74.7%, respectively (p>0.05). Meanwhile, PFS and OS rates for group A were significantly better than those for group B (35.3% vs. 13.3%, p=0.010; and 46.3% vs. 13.3%, p=0.009, respectively). Conclusion: Our data revealed considerable prognostic heterogeneity in disseminated cervical cancer. Even though a high PCR was achieved in patients treated with definitive RT, survival outcomes were dependent on progression of visceral organ metastasis. Therefore, personalized RT and chemotherapy treatment strategies according to the presence of visceral organ metastasis in disseminated cervical cancer patients may help improve clinical outcomes.

AB - Background: To investigate the role of radiotherapy (RT) in and to suggest radiotherapeutic strategies for patients presenting with disseminated cervical cancer. Methods: We retrospectively analyzed 50 patients diagnosed as the disseminated cervical cancer with distant lymph nodal or visceral organ metastasis between September 1980 and August 2012. Patients were divided into two subgroups according to visceral organ metastasis: 35 patients diagnosed with distant lymph node metastasis only (group A) and 15 patients with visceral organ metastasis (group B). All patients received external beam RT to the pelvis (median dose 45 Gy) and high-dose rate intracavitary RT (median dose 30 Gy). Thirty-nine patients (78%) received chemotherapy. Results: Median follow-up time was 74 months. The 5-year pelvic control rate (PCR) was 85.8%, and the progression-free survival (PFS), and overall survival (OS) rates were 28.7%, and 36.2%, respectively. The major treatment failure was systemic progression (32 patients, 64%). The 5-year PCRs in groups A and B were 87.4% and 74.7%, respectively (p>0.05). Meanwhile, PFS and OS rates for group A were significantly better than those for group B (35.3% vs. 13.3%, p=0.010; and 46.3% vs. 13.3%, p=0.009, respectively). Conclusion: Our data revealed considerable prognostic heterogeneity in disseminated cervical cancer. Even though a high PCR was achieved in patients treated with definitive RT, survival outcomes were dependent on progression of visceral organ metastasis. Therefore, personalized RT and chemotherapy treatment strategies according to the presence of visceral organ metastasis in disseminated cervical cancer patients may help improve clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84927539540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927539540&partnerID=8YFLogxK

U2 - 10.1186/s13014-015-0373-0

DO - 10.1186/s13014-015-0373-0

M3 - Article

VL - 10

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 77

ER -